Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Definium Therapeutics Inc (DFTX)

Definium Therapeutics Inc (DFTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,261,151
  • Shares Outstanding, K 99,698
  • Annual Sales, $ 0 K
  • Annual Income, $ -183,790 K
  • EBIT $ -166 M
  • EBITDA $ -168 M
  • 60-Month Beta 2.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.68

Options Overview Details

View History
  • Implied Volatility 92.32% (+15.50%)
  • Historical Volatility 49.93%
  • IV Percentile 86%
  • IV Rank 61.56%
  • IV High 111.14% on 03/03/26
  • IV Low 62.19% on 04/15/26
  • Expected Move (DTE 25) 4.21 (17.91%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 3,042
  • Volume Avg (30-Day) 1,785
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 46,271
  • Open Int (30-Day) 40,355
  • Expected Range 19.28 to 27.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.49
  • Number of Estimates 4
  • High Estimate $-0.46
  • Low Estimate $-0.54
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.13 +36.84%
on 03/30/26
26.24 -10.67%
on 04/20/26
+5.04 (+27.39%)
since 03/20/26
3-Month
15.61 +50.11%
on 02/13/26
26.24 -10.67%
on 04/20/26
+6.66 (+39.69%)
since 01/20/26
52-Week
5.51 +325.41%
on 04/21/25
26.24 -10.67%
on 04/20/26
+17.67 (+306.24%)
since 04/17/25

Most Recent Stories

More News
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric...

DFTX : 22.96 (+1.23%)
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 22.96 (+1.23%)
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

The annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5.4% in 2020 to 6.6% in 2023 The 3-year total prevalence of GAD reached 10.3%,...

DFTX : 22.96 (+1.23%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 22.96 (+1.23%)
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 22.96 (+1.23%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 22.96 (+1.23%)
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required;...

DFTX : 22.96 (+1.23%)
Definium Therapeutics to Participate at Upcoming Investor Conferences

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying...

DFTX : 22.96 (+1.23%)
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying...

DFTX : 22.96 (+1.23%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of...

DFTX : 22.96 (+1.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK....

See More

Key Turning Points

3rd Resistance Point 24.11
2nd Resistance Point 23.55
1st Resistance Point 23.12
Last Price 22.96
1st Support Level 22.13
2nd Support Level 21.57
3rd Support Level 21.14

See More

52-Week High 26.24
Last Price 22.96
Fibonacci 61.8% 18.32
Fibonacci 50% 15.88
Fibonacci 38.2% 13.43
52-Week Low 5.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.